Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Obexelimab in Patients With Relapsing Multiple Sclerosis

NCT06564311 is registered in ClinicalTrials.gov with Zenas BioPharma (USA), LLC as lead sponsor.

NCT NCT06564311
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06564311 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Obexelimab in Patients With Relapsing Multiple Sclerosis
Lead sponsor
Zenas BioPharma (USA), LLC
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 26, 2024
Completion date
February 28, 2026
Enrollment
93 (estimated)
Sites
47

Conditions

As the registry lists them; a condition with its own page is linked.

relapsing multiple sclerosis